Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan B Sandler

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Phase III clinical trial development: a process of chutes and laddersDavid M Dilts, Steven K Cheng, Joshua S Crites, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599Suzanne E Dahlberg, Alan B Sandler, Julie R Brahmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2012
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumabTien Hoang, Suzanne E Dahlberg, Alan B Sandler, et al.
Cancer Treatment Reviews|April 27, 2020
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I Hurwitz, Alan B Sandler, et al.
Chest|October 6, 2007
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)Mark A Socinski, Richard Crowell, Thomas E Hensing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501Leora Horn, Suzanne E Dahlberg, Alan B Sandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee, Wei Wang, Joan H Schiller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumabAlan B Sandler, Joan H Schiller, Robert Gray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2013
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trialsSuzanne E Dahlberg, Joan H Schiller, Philip B Bonomi, et al.
Oncology|July 26, 2002
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group StudyKristen N Ganjoo, Michael S Gordon, Alan B Sandler, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Phase III clinical trial development: a process of chutes and laddersDavid M Dilts, Steven K Cheng, Joshua S Crites, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599Suzanne E Dahlberg, Alan B Sandler, Julie R Brahmer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 31, 2012
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumabTien Hoang, Suzanne E Dahlberg, Alan B Sandler, et al.
Cancer Treatment Reviews|April 27, 2020
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookJosep Garcia, Herbert I Hurwitz, Alan B Sandler, et al.
Chest|October 6, 2007
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)Mark A Socinski, Richard Crowell, Thomas E Hensing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501Leora Horn, Suzanne E Dahlberg, Alan B Sandler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee, Wei Wang, Joan H Schiller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumabAlan B Sandler, Joan H Schiller, Robert Gray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2013
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trialsSuzanne E Dahlberg, Joan H Schiller, Philip B Bonomi, et al.
Oncology|July 26, 2002
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group StudyKristen N Ganjoo, Michael S Gordon, Alan B Sandler, et al.
Pageof 7